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Dysferlin regulates cell membrane repair by facilitating
injury-triggered acid sphingomyelinase secretion
A Defour1, JH Van der Meulen1, R Bhat1, A Bigot2, R Bashir3, K Nagaraju1,4 and JK Jaiswal*,1,4
Dysferlin deficiency compromises the repair of injured muscle, but the underlying cellular mechanism remains elusive. To study this
phenomenon, we have developed mouse and human myoblast models for dysferlinopathy. These dysferlinopathic myoblasts
undergo normal differentiation but have a deficit in their ability to repair focal injury to their cell membrane. Imaging cells undergoing
repair showed that dysferlin-deficit decreased the number of lysosomes present at the cell membrane, resulting in a delay and
reduction in injury-triggered lysosomal exocytosis. We find repair of injured cells does not involve formation of intracellular
membrane patch through lysosome–lysosome fusion; instead, individual lysosomes fuse with the injured cell membrane, releasing
acid sphingomyelinase (ASM). ASM secretion was reduced in injured dysferlinopathic cells, and acute treatment with
sphingomyelinase restored the repair ability of dysferlinopathic myoblasts and myofibers. Our results provide the mechanism for
dysferlin-mediated repair of skeletal muscle sarcolemma and identify ASM as a potential therapy for dysferlinopathy.
Cell Death and Disease (2014) 5, e1306; doi:10.1038/cddis.2014.272; published online 26 June 2014
Dysferlinopathy is a progressive muscle wasting disease,
which is classified as limb-girdle muscular dystrophy type 2B
(LGMD2B) or Miyoshi muscular dystrophy 1, based on its
muscle involvement.1,2 Dysferlin deficit leads to altered
vesicle formation and trafficking,3,4 poor repair of injured cell
membranes,5,6 and increased muscle inflammation.7,8 Dys-
ferlin contains C2 domains that are found in Ca2þ -dependent
membrane fusion proteins such as synaptotagmins.9 Thus,
dysferlin is thought to regulate muscle function by regulating
vesicle trafficking and fusion.10–13 Dysferlin deficiency has
also been implicated in conflicting reports regarding the fusion
ability of dysferlinopathic myoblasts.4,14–16 With such diverse
roles for dysferlin, the mechanism through which dysferlin
deficiency results in muscle pathology is unresolved. As
skeletal muscle-specific re-expression of dysferlin rescues all
dysferlinopathic pathologies,17,18 myofiber repair has been
suggested to be the unifying deficit underlying muscle
pathology in dysferlinopathy.19 Repair of injured cell mem-
branes requires subcellular compartments, which in mamma-
lian cells include lysosomes,11 enlargeosomes,20 caveolae,21
dysferlin-containing vesicles,5 and mitochondria.22
Cells from muscular dystrophy patients that have normal
dysferlin expression exhibit normal lysosome and enlargeo-
some exocytosis.23 However, dysferlinopathic muscle cells
exhibit enlarged LAMP2-positive lysosomes, reduced fusion of
early endosomes, altered expression of proteins regulating late
endosome/lysosome fusion, and reduced injury-triggered cell-
surface levels of LAMP1.4,11,12 In non-muscle cells, lack of
dysferlin reduces lysosomal exocytosis.24 These findings
implicate lysosomes in dysferlin-mediated muscle cell
membrane repair. In one model for lysosome-mediated cell
membrane repair, Ca2þ triggers vesicle–vesicle fusion near
the site of injury, forming ‘membrane patch’, which fuses to
repair the wounded cell membrane.25–28 In another model,
lysosome exocytosis following cell membrane injury by pore-
forming toxins leads to secretion of the lysosomal enzyme acid
sphingomyelinase (ASM), which causes endocytosis of pores
in the damaged cell membranes.21,29,30 Both these models
have been suggested to be involved in the repair of injured
muscle cells.21,28
To examine the muscle cell pathology in dysferlinopathy,
we have developed dysferlinopathic mouse and human
models. Use of these models shows that a lack of dysferlin
does not alter myogenic differentiation but causes poor repair
of even undifferentiated muscle cells. We show that dysferlin
is required for tethering lysosomes to the cell membrane.
Fewer lysosomes at the cell membrane in dysferlinopathic
cells results in slow and reduced lysosome exocytosis
following injury. This reduction in exocytosis reduces
injury-triggered ASM secretion, which is responsible for the
poor repair of dysferlinopathic muscle cells. Extracellular
sphingomyelinase (SM) fully rescues the repair deficit in
dysferlinopathic cells and mouse myofibers, offering a
potential drug-based therapy for dysferlinopathy.
Results
Dysferlin-deficient myoblasts undergo normal growth
and differentiation. To characterize the role of dysferlin in
myogenic cell growth and differentiation, we used two cellular
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models: (1) the C2C12 cell line, derived from a pool of cells
with shDNA-mediated knockdown of dysferlin (C2C12-
shRNA), and corresponding vector control cells (C2C12),31
and (2) a primary mouse myoblast clone isolated from
immortomice carrying the A/J allele of dysferlin (dysf-KO) or
the corresponding immortomice carrying normal dysferlin
allele (dysf-wild type (WT)).32 Western blot analysis showed
no detectable dysferlin expression in C2C12-shRNA or
primary dysferlinopathic mouse myoblasts (Figures 1a and e).
Following differentiation, dysferlin expression increased in
the control cells, whereas dysferlinopathic cells still showed
no detectable dysferlin expression (Figures 1a, b, e and f).
Immunostaining of myotubes showed that as in control cells,
the dysferlinopathic cells were able to form myotubes, but
they lacked any detectable dysferlin expression (Figures 1c
and g). Additionally, genotyping confirmed dysferlin mutation
in dysf-KO myoblasts (Figure 1h).
To assess growth, we compared the doubling time for
control and dysferlinopathic cells and found the times to be
comparable: 17 h for C2C12 versus 16 h for C2C12-shRNA
cells (Figure 1d). We also found comparable doubling times
for mouse myoblasts: 17 h for WT-dysf versus 21 h for dysf-
KO (Supplementary Figure 1A). In view of the proposed
involvement of dysferlin in myogenesis through the regulation
of myoblast fusion,31 we assessed the differentiation of these
cells by monitoring the expression of myogenic markers,
including desmin, myogenin, a-actinin, and myosin heavy
chain 3. Expression of all these myogenic markers increased
similarly and steadily during the myogenic differentiation
of control and dysferlinopathic cells and resulted in
myotubes that were indistinguishable from each other
(Figures 1b, c, f and g).
Dysferlin deficiency compromisesmyoblast cell membrane
repair. Studies of laser-induced injury have established a
role for dysferlin in sarcolemmal repair of myofibers and
myotubes.5,15 To determine whether dysferlin also regulates
myoblast cell membrane repair, we used two different cell
injury approaches.23,33 In the first approach, a population of
cells was injured using glass beads; all the injured cells were
labeled with FITC-dextran, and cells that failed to repair got
labeled with FITC- and TRITC-dextran (Figure 2a).33 This
approach showed that twice as many dysferlinopathic
myoblasts (C2C12-shRNA: 30±2% and dysf-KO: 25±3%)
as control myoblasts (C2C12: 15±2% and dysf-WT:
11±2%) showed a failure to repair (Figure 2b).
In the second approach, cell membrane repair kinetics were
monitored following injury with a pulsed 1-photon laser in the
presence of the membrane-impermeant lipid dye FM1-
43.22,33 Because cell membrane repair depends on calcium,
we established the sensitivity of this assay by injuring cells in
the presence or absence of calcium. In the presence of
calcium, FM dye entry ceased within a minute of injury,
whereas it continued even at 4min in the absence of calcium
(Figure 2c and Supplementary Figure 2A). Next, we assessed
the repair of C2C12-shRNA myoblasts in the presence of
calcium. Unlike the control C2C12 cells (Supplementary
Video 1), FM dye entry into C2C12-shRNA cells continued
even at 4min after injury (albeit to a lesser extent than C2C12
cells injured in the absence of calcium; Figure 2d and
Supplementary Figure 2B, Supplementary Video 2). This
result indicates that dysferlinopathic myoblasts, although
capable of repair, are less efficient than healthy myoblasts
in their repair ability.
Dysferlinopathic muscle cells show reduced injury-
triggered lysosomal exocytosis. In view of the depen-
dence of cell membrane repair on lysosome exocytosis34 and
dysferlin,5 we investigated lysosomal exocytosis in dysferli-
nopathic myoblasts. To quantify the glass bead injury-
induced increase in the cell-surface level of the lysosomal
protein LAMP1, we injured myoblasts in the presence of
TRITC-dextran (causing red staining of injured cells) and
then probed for cell-surface LAMP1 in live cells using an
antibody specific for the luminal domain of LAMP1.33,34
Using this approach, we have previously demonstrated that,
independent of repair ability, cells that exocytose lysosomes
show increased cell-surface LAMP1, whereas cells that fail to
exocytose lysosomes do not.33 As compared with uninjured
myoblasts, we detected more LAMP1 on the surface of
injured myoblasts (Figure 3a). Dysferlinopathic myoblasts
showed significantly reduced (35% for dysf-KO, 30% for
C2C12-shRNA) cell-surface LAMP1 when compared with
corresponding healthy controls (Figures 3b and c).
To establish whether the reduction in cell-surface LAMP1
was due to a reduction in injury-triggered lysosomal exocy-
tosis, we monitored exocytosis of individual lysosomes
following laser injury. Lysosomes were labeled with the
luminal marker FITC-dextran and imaged using TIRF.33
As in our previous findings with calcium agonists,35,36
we observed injury-triggered exocytosis of individual lysosomes,
as demonstrated by secretion of FITC-dextran by individual
lysosomes (Figure 3d and Supplementary Video 3,4).
Dysferlinopathic myoblasts undergoing repair showed a
decreased number of injury-triggered exocytic events
(42-fold for dysf-KO, Figures 3d and e and Supplementary
Figure 1C; 20% for C2C12-shRNA, Supplementary
Figure 1B). A similar deficit was also observed when these
cells were triggered with calcium ionophore (Figures 3f and g).
These results demonstrate that reduced injury-triggered
lysosomal exocytosis in dysferlinopathic cells is the result of
a deficit in Ca2þ -triggered lysosomal exocytosis.
In view of the patch model for cell membrane repair, we
expected lysosomes to undergo Ca2þ -triggered homotypic
fusion to form a ‘membrane patch’,25,27,37 followed by one
large FITC-dextran flash caused by exocytosis of the patch
vesicle. However, instead of homotypic calcium-triggered
lysosome fusions we observed exocytosis of individual
lysosomes to the injured cell membrane (Figures 3d–g).
A variant of the patch model would involve compound
exocytosis of lysosomes at the site of focal injury. We
therefore examined the localization of exocytic events with
respect to the site of injury. Each cell was divided into two
equal halves along the long axis of the cell drawn from the site
of injury, and exocytic events were quantified in the two halves
(near and away from the site of injury). Exocytic events were
uniformly distributed throughout the cell in WT and dysferlino-
pathic cells (Figures 3h and i), indicating that lysosome-
mediated repair of the muscle cell membrane does not
proceed by membrane patch formation.
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Dysferlin is required for tethering lysosomes to the cell
membrane. It was primarily the lysosomes present at the
cell membrane whose exocytosis was triggered by cell injury
(Supplementary Video 4). Preferential involvement of cell
membrane-proximal lysosomes suggested a need for rapid
lysosomal exocytosis for efficient membrane repair. We
therefore examined the kinetics of injury-triggered lysosomal
exocytosis in healthy and dysferlinopathic cells. Lysosomal
exocytosis was triggered within seconds of injury and
continued over the next couple of minutes as the cells
underwent repair (Figures 4a and b). More than half of all
exocytic events occurred within the first 15 s of injury, and it
was the exocytosis of this pool of lysosomes that was
reduced (B3-fold) in dysferlinopathic cells (Figures 4a and b).
There was no difference in the subsequent exocytic events
between WT and dyferlinopathic cells, indicating that, unlike
the dysferlin homologs the synaptotagmins, the lack of which
prevents vesicle exocytosis,38 a lack of dysferlin delays
but does not totally prevent calcium-triggered lysosomal
exocytosis. This role of dysferlin in delaying (rather than
blocking) lysosomal exocytosis may explain why the health of
dysferlinopathic cells is poor, but they are not incapable of
repair (Figures 2b and d and Supplementary Figure 2B).
In view of the recently identified role of dysferlin in stabilizing
Ca2þ signaling in response to osmotic stress-induced
myofiber injury,39 we asked whether altered lysosome
exocytosis in dysferlinopathic cells is the result of a change
in the kinetics of the injury-triggered Ca2þ increase in these
cells. Using Fluo-4, we measured injury-triggered cytosolic
Ca2þ dynamics and found no difference in the initiation and
amplitude of the injury-triggered cytosolic Ca2þ increase
between the control and dysferlinopathic cells (Figures 4c, d
and f and Supplementary Figure 2C). However, in agreement
with the slower repair of dysferlinopathic cells, an injury-
triggered increase in cytosolic Ca2þ took longer to return to
pre-injury values (Figures 4e and f and Supplementary
Figure 2C).
Thus, in dysferlinopathic cells, reduced lysosomal exo-
cytosis occurs in the first 15 s of injury despite the similar
kinetics and amplitude of injury-triggered increase in cytosolic
Ca2þ in WT and dysferlinopathic cells. This finding suggests
that a deficit in an alternate function ascribed to synaptotag-
mins: vesicle docking and priming may be the basis for the
delayed injury-triggered lysosomal exocytosis in cells lacking
dysferlin. To test this hypothesis, we used TIRF imaging to
analyze the number of lysosomes at the cell membrane in WT
and dysferlinopathic cells and found a decrease of up to 30%
in cell membrane-proximal lysosomes in the dysferlinopathic
cells (Figures 4g and h). Because re-expression of dysferlin
rescues the deficit in muscle cell membrane repair,17 we
tested the effect of dysferlin re-expression on membrane-
proximal lysosomes in dysferlinopathic cells. Expression
of human dysferlin in C2C12-shRNA cells restored the
number of cell membrane-proximal lysosomes to WT levels
Figure 1 Dysferlin deficiency does not alter myoblast proliferation or differentiation. (a and e) Western blot analysis of dysferlin expression in three independent cultures
each of myoblasts and myotubes (following 4 days of differentiation): (a) C2C12 and C2C12-shRNA and (e) dysf-WT and dysf-KO myoblasts. (b and f) Western blot analysis of
expression of various muscle differentiation markers tested following the indicated days of differentiation in (b) C2C12 and C2C12-shRNA and (f) dysf-WT and dysf-KO
myoblasts. (c and g) Immunostaining of dysferlin (green) and LAMP1 (red) in (c) C2C12 and C2C12-shRNA and (g) dysf-WT and dysf-KO myotubes following 4 days of
differentiation. Scale bar: 50mm. (d) Plot showing doubling time for C2C12 and C2C12-shRNA myoblasts in culture during 4 days of proliferation (n¼ 8 cell cultures; error bars
show the extreme values). (h) PCR analysis of genomic DNA from dysf-WT and dysf-KO myoblasts using primers to identify the presence of the full-length dysferlin allele
(Dysf) and the dysferlin allele with the insertion of a retrotransposon (Etn) in the dysferlin gene
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(Figure 4i). This result demonstrates that re-expression of
dysferlin restores the ability of the exocytic lysosomes to be
tethered to the cell membrane and correlates well with
previous reports of improved sarcolemmal repair as a result
of dysferlin re-expression.17,40 To determinewhether dysferlin
regulates lysosome tethering by being localized to lysosomes,
we examined whether dysferlin localizes to LAMP1-labeled
lysosomes. We found that dysferlin (and dysferlin-GFP)
localized to the cell membrane, endoplasmic reticulum, and
some vesicular structures but did not co-localize with
lysosomes (Figures 4j and k).
ASM is a potential drug therapy for dysferlinopathy.
With no evidence to support the membrane patch model
(Figures 3h and i), we next examined the model describing
lysosome-mediated repair of cell membranes injured by
pore-forming toxins.29 According to this model, injury-
triggered secretion of lysosomal ASM facilitates repair.29,30,41
In view of the lysosomal exocytosis defects in dysferlino-
pathic cells, this model predicts a reduced/delayed secretion
of ASM by these cells and further predicts that the deficit in
ASM secretion would cause poor sarcolemmal repair. To test
these hypotheses, we first examined the ASM expression in
healthy and dysferlinopathic C2C12 cells and found their
levels to be similar (Figure 5a, upper panel). Next, we asked
whether, as in injury mediated by pore-forming toxins,
mechanical injury would also trigger ASM secretion. Western
blot analysis of culture supernatants of mechanically
(scrape)-injured C2C12 and C2C12-shRNA cells allowed to
repair for 5min showed injury-triggered ASM secretion by
both types of cell. Despite their equal cellular ASM levels
(Figure 5a total ASM, lower panel), dysferlinopathic cells
secreted less ASM than the corresponding control cells
(Figure 5a secreted ASM, lower panel). To assess mechan-
ical injury-triggered ASM secretion, we compared ASM
activity in culture supernatants of C2C12 and C2C12-shRNA
myoblasts following repair from scrape injury. Secreted ASM
activity was reduced by 70% in dysferlinopathic C2C12-
shRNA myoblasts, when compared with the healthy C2C12
cells (Figure 5b).
The observations reported above suggested that reduced
ASM secretion as a result of defective lysosome docking and
exocytosis correlates with poor repair of dysferlinopathic
myoblasts. Therefore, we hypothesized that providing extra-
cellular SM to injured dysferlinopathic cells could rescue their
repair deficit. To test this hypothesis, we incubated dysferlino-
pathic myoblasts with 2U/ml of SM and then injured them in
the presence of FM dye. The presence of extracellular SM
fully restored repair of C2C12-shRNA myoblasts after
focal laser injury (Figure 5c, Supplementary Figure 3A,
Supplementary Video 5).
To examine whether extracellular SM could serve as a
potential therapy for dysferlinopathic patients, we used
immortalized myoblasts derived from a LGMD2B patient.
These cells lacked detectable dysferlin expression
(Supplementary Figures 3B and C). As in the other
Figure 2 Dysferlinopathic myoblasts show poor cell membrane repair. (a) C2C12 cells injured in the presence of FITC-dextran (green) were allowed to undergo repair in
TRITC-dextran (red) and then stained with Hoechst 33342 (blue). Uninjured cells are not labeled with dextran (upper left panel); injured cells are labeled green, and cells that
failed to repair themselves are labeled red and green. Upper panels show uninjured myoblasts and myoblasts that failed to repair themselves because of a lack of Ca2þ .
Lower panel shows C2C12 and C2C12-shRNA myoblasts injured and allowed to repair themselves in the presence of Ca2þ ; Scale bar: 50mm. (b) Images of glass bead-
injured cells were quantified (4100 cells each) and are presented as the fraction of cells that failed to show repair in the presence of Ca2þ . (c) FM1-43 influx following focal
laser injury in410 myoblasts injured in the presence of Ca2þ shows efficient repair from laser injury; cells injured in the absence of Ca2þ do not. (d) Quantification of FM1-43
influx by time-lapse imaging of 415 myoblasts each following injury in the presence of Ca2þ , showing poor healing of C2C12-shRNA myoblasts. Data in b, c and d show
means±S.E.M.; ***Po0.001 by unpaired Student’s t-test
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dysferlinopathic mouse myoblast models described here,
myoblasts from this LGMD2B patient also formed normal
myotubes (Supplementary Figure 3B). We then tested the cell
membrane-repair capacity of these myoblasts and found that
the patient’smyoblasts did indeed have a compromised ability to
repair their cell membranes (Figures 5d and e and
Supplementary Videos 6 and 7). This cell membrane repair
deficit in patient-derivedmyoblastswas fully reversed by treating
the cells with extracellular SM (Figure 5f, Supplementary Figure
S3D and Supplementary Videos 7 and 8).
To further evaluate the utility of extracellular SM treatment
for improving dysferlinopathic muscle repair, we next tested
the efficacy of SM treatment in rescuing the repair deficit of
dysferlinopathic myofibers. For this purpose, we used exten-
sor digitorum longus (EDL) and bicepsmuscles isolated from a
dysferlin-deficient B6.A/Jmouse.18 As compared with the EDL
myofibers from parental WT (C57BL/6) mice, EDL myofibers
fromB6.A/Jmice exhibited a significantly reduced repair ability
(Figures 6a and b). EDL and biceps muscles injured following
acute addition of 0.5U/ml SM (without any pre-treatment) fully
rescued the repair deficit seen in the dysferlinopathic
myofibers (Figures 6a–c, Supplementary Videos 9 and 10).
It has been shown that extended exposure to SM leads to
mitochondrial ROS production and reduced muscle contrac-
tile force.42 However, recombinant ASM delivered in vivo (in
mice) is rapidly cleared from circulation, 40% within 1min of
delivery.43 Therefore, we examined the effect of brief SM
treatment on the contractile force, fatigue, and force–
frequency relationships in muscle from B6.A/J mice. We
observed that the same SM treatment, which improved the
repair ability of the myofibers (5min treatment with 0.5U/ml
SM; Figures 6a–c), had no detectable effect on the specific
force (Figure 6d), force–frequency relation (Figure 6e), or
fatigability (Figure 6f) of the EDL muscle from B6.A/J mice.
Discussion
Despite over a century of research in the field of muscle injury
and repair, there is still little understanding of the cellular
mechanism involved in repairing injured myofibers. A decade
ago, the discovery of dysferlin’s role in the repair of injured
myofibers offered the first suggestion that fusion of cellular
vesicles is involved in the repair of injured muscle fibers.5
However, the identity of the vesicle responsible for mediating
Figure 3 Dysferlin deficiency reduces injury-triggered lysosomal exocytosis. (a) dysf-WT and dysf-KO myoblasts wounded in the presence of Ca2þ by glass beads in
medium containing TRITC-dextran were stained for cell-surface LAMP1 (left panel); White arrows indicate the injured cells labeled (red) by TRITC dextran. Scale bar: 50mm.
(b and c) Reduced cell-surface LAMP1 staining in dysferlinopathic myoblasts following injury in the presence of Ca2þ : cell-surface LAMP1 staining was quantified for4400
dysf-WT, dysf-KO, C2C12, and C2C12-shRNA myoblasts each. (d and f) TIRF images showing dysf-WT myoblasts with FITC-dextran-labeled lysosomes. ‘X’ marks the sites
of lysosome fusion following (d) laser injury or (f) ionomycin treatment. The orange line denotes the cell boundary. The inset in d shows a zoomed view of one lysosome as it
underwent fusion, releasing FITC-dextran. Scale bar: 10 mm. (e and g) Quantification of lysosome fusions in 413 dysf-WT and dysf-KO myoblasts, showing a reduced
number of fusion events in dysferlinopathic myoblasts following (e) laser injury (168 lysosome fusions for dys-WT and 88 for dys-KO) and (g) ionophore treatment (264 fusions
for dys-WT and 112 for dys-KO). (h and i) Localization of lysosome exocytosis sites (168 for dys-WT, 88 for dys-KO, 350 for C2C12, and 385 for C2C12-shRNA) with respect to
the site of injury in (h) C2C12 or (i) primary myoblasts (nZ10 cells each). Data are mean±S.E.M. * Po0.05 and ***Po0.001 by unpaired Student’s t-test
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the repair of injuredmyofibers and the role that dysferlin has in
this process have remained elusive. Understanding how
injured myofibers undergo repair is not only crucial because
muscle injury is widespread but also because the lack of this
knowledge has hampered the development of therapies for
muscular dystrophies, including LGMD2B,Miyoshi myopathy,
LDMD2L, and dystroglycanopathies, all of which are asso-
ciated with poor sarcolemmal membrane repair.5,23,44
Some of the effects of dysferlin deficiency on muscle tissue
have been attributed to poor differentiation of the dysferlino-
pathic myoblasts.4,32 The various mouse and human myo-
blast cell lines we have described here, although useful for
studying the cell biological aspects of dysferlin deficiency in
muscle cells in vitro, do not support a role for dysferlin
deficiency in myoblast differentiation in culture. Thus, these
cells are not suitable for testing any potential effect of dysferlin
on muscle cell differentiation. However, our finding, across all
these mouse and human cellular models, that dysferlin
deficiency causes poor repair of dysferlinopathic myoblasts
makes these cells an excellent model for screening drugs to
improve the repair of dysferlinopathicmuscle cell membranes.
We also show that a lack of dysferlin results in delayed and
reduced lysosome exocytosis as a result of poor tethering
of lysosomes to the cell membrane (Figures 3 and 4). This
reduced exocytosis may explain the subsarcolemmal vesicle
accumulation reported in dysferlin-deficient muscles,45 and it
Figure 4 Dysferlin regulates tethering of lysosomes to the cell membrane and kinetics of injury-triggered lysosome exocytosis. (a and b) Histogram showing averaged
kinetics of lysosome exocytosis following laser injury (nZ10 cells) in (a) C2C12 and (b) primary myoblasts. Note that it is only the earliest exocytic events that are reduced in
dysferlinopathic myoblasts. (c) Quantification of the peak increase in Fluo-4 emission following laser injury in C2C12 and C2C12-shRNA myoblasts (n47 cells). (d) Time
taken following laser injury for the Fluo-4 intensity to reach the peak value (n47 cells) in C2C12 cells. (e) Time following laser injury for the increase in Fluo-4 intensity to return
to pre-injury level (n47 cells). (f) Plot showing injury-triggered change in Fluo-4 intensity for a representative C2C12 and C2C12-shRNA cell. (g and h) Quantification of cell
membrane-proximal lysosomes in (g) C2C12 and C2C12-shRNA and (h) dysf-WT and dysf-KO myoblasts (nZ20 cells each), with fewer cell membrane-proximal lysosomes
in dysferlinopathic cells. (i) Quantification of cell membrane-proximal lysosomes, showing that transient expression of dysferlin-GFP in C2C12-shRNA myoblasts (n¼ 10)
increases the number of cell membrane-proximal lysosomes to a level similar to C2C12. (j) Representative confocal image of a human myoblast immunolabeled for
endogenous dysferlin (green) and LAMP1 (red), showing little lysosomal localization of dysferlin. (k) Confocal image of a C2C12 myoblast expressing dysferlin-GFP also
shows lack of lysosomal localization of dysferlin. Scale bar: 10 mm. All data are means±S.E.M. *Po0.05 and ***Po0.001 for the comparison of mutant and corresponding
WT samples; ##Po0.01 for the comparison to untransfected C2C12-shRNA; all compared by unpaired Student’s t-test
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is in agreement with the increased accumulation of lysosomes
reported in dysferlinopathic muscle cells.4
Despite the requirement of dysferlin for cell membrane
localization of lysosomes, we find that dysferlin itself is not
localized to lysosomes. This supports previous reports that
dysferlin is localized to the sarcolemma and T-tubules,46 but
not to lysosomes.28 This also makes dysferlin similar to the
cell membrane-localized synaptotagmin isoform, which
regulate calcium-triggered vesicle tethering/fusion of the
vesicle to the cell membrane by interacting with vesicular
SNARES or synaptotagmins.47 Some of the dysferlin-
interacting molecules have been identified and include
injury-sensing48 and fusion-regulating proteins such as
annexins.11 However, further work is needed to identify the
SNAREs and lysosomal proteins that interact with dysferlin
and facilitate lysosome docking and fusion to the injured
cell membrane.
Through live imaging of lysosomes, we have shown
here that lysosome-mediated sarcolemmal repair does not
involve the proposed membrane patch model of cell
membrane repair. Instead, lysosomes tethered to the cell
membrane exocytose individually in response to injury,
resulting in injury-triggered secretion of ASM. This process
is compromised in the dysferlinopathic cells and is the
basis for the poor repair of dysferlinopathic muscle. By
demonstrating reduced lysosomal exocytosis and reduced
ASM secretion by dysferlinopathic muscle cells, our study
offers direct evidence in support of a role for ASM secretion in
the repair of mechanical injury to dysferlinopathic muscle cells
and myofibers. The mechanism of this repair may involve
endocytosis21,29 and bleb formation,30,41 which are proposed
on the basis of pore-forming toxin-induced injury. However, it
is worth noting that the repair of dysferlinopathic sarcolemma
after pore-forming toxin-mediated injury is distinct from the
repair after mechanical injury, as dysferlin-deficient muscle
recovers normally from sarcolemmal damage caused by the
cell membrane pore-forming plant metabolite saponin.49
Other effects of ASM could be mediated by its ability to
hydrolyze cell membrane sphingomyelin. This hydrolysis
would result in the formation of membrane microdomains,
which can regulate signaling, fluidity, and cytoskeleton
organization at the cell membrane,50,51 processes that
regulate membrane properties and cell membrane repair.52,53
In agreement with a role for membrane properties in the repair
of injured membranes, we recently observed that the use of a
membrane-active steroid analog improves the repair of
injured cell membranes.54 Thus, additional work is needed
to elucidate the complete sequence of steps by which reduced
ASM secretion following mechanical injury results in poor
repair of dysferlinopathic muscle.
Beyond regulating sarcolemmal properties and sarco-
lemmal repair, ASM can also aid in the repair of injured
Figure 5 Reduced ASM secretion by dysferlinopathic cells and rescue of their repair ability by sphingomyelinase (SM) treatment. (a) Western blot for cellular ASM
expression in three independent C2C12 cultures (upper panel). Lower panel shows the same for a representative experiment in which the scrape injury-triggered secretion of
ASM was compared in C2C12 and C2C12-shRNA cells. (b) Activity levels of secreted ASM after scrape injury of C2C12 and C2C12-shRNA myoblast cultures (n¼ 4).
(c) Quantification of FM1-43 influx following laser injury of C2C12 myoblasts and SM-treated and untreated C2C12-shRNA myoblasts (n¼ 17 cells each). Note the rescue of
the repair deficit in C2C12-shRNA cells by SM treatment. (d) Time-lapse images and (e) quantification (n416 cells each) showing FM1-43 influx in control or LGMD2B patient
myoblasts following focal laser injury, with poor repair of patient myoblasts. Scale bar: 100mm. White box marks the injured region. (f) Quantification of FM1-43 influx following
laser injury in control and SM-treated (2 U/ml) or untreated LGMD2B patient myoblasts (n419 myoblasts each), showing full rescue of the repair defect in patient myoblasts.
Data are means±S.E.M. *Po0.05, **Po0.01, and ***Po0.001 (comparison of mutant and corresponding WT samples); ##Po0.01 and ###Po0.001 (treated versus
untreated dysferlinopathic samples) compared by unpaired Student’s t-test
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muscle tissue through its other roles in reducing muscle
contractile force and the calcium sensitivity of the muscle
contractile apparatus.42 This role of ASM could protect the
injured muscle by reducing the potential for contraction-
induced re-injury. Also, the ASM-ceramide systemcan regulate
inflammation by regulating the release of pro-inflammatory
cytokines.55 Finally, by increasing basal and insulin-induced
glucose uptake in skeletal muscles,56 ASM can increase
metabolism and aid the recovery of injured muscle cells.
Dysferlin deficiency could affect one or more of the above-
mentioned benefits of injury-triggered ASM secretion. Thus, in
addition to the myofiber repair deficit, reduction in these effects
of ASM could further contribute to poor repair of dysferlino-
pathic muscles. Thus, our results not only identify the cellular
mechanism underlying the poor repair of dysferlinopathic
muscle but also point to novel aspects of dysferlin deficit on
muscle repair.
Our finding that acute SM treatment is sufficient to improve
the repair ability of the dysferlinopathic myofibers demon-
strates its potential as a therapy for dysferlinopathy.
Deleterious effect of long-term SM treatment on muscle
function is a source of some concern.42 However, our findings
that acute treatment with SM does not negatively affect
muscle contractility and excitation contraction coupling
together with the known rapid ASM washout kinetics
in vivo43 alleviate this potential confounding factor. In addition,
there has been significant progress made in preclinical and
clinical trials aimed at ASM-based therapy for another rare
genetic disorder, Niemann-Pick syndrome.57 In view of these,
ASM treatment is as a therapeutic option that could be
evaluated for its clinical efficacy for dysferlinopathic patients.
Materials and Methods
Cell culture. The stable C2C12-shRNA mouse clone was derived from a
C2C12 dysferlin shRNA pool, as described elsewhere.31 Immortalized mouse
primary cells, dysf-WT and dysf-KO, were a gift from Dr Terry Partridge and were
derived from EDL fibers as described previously.32 Human cells were isolated from
the quadriceps muscle of a dysferlinopathic 17-year-old male with a homozygous
mutation in exon 44 that resulted in a c.4882G4A mutation; they were a gift from
Dr Eduardo Gallardo. Control myoblasts were isolated from the pectoralis major
muscle of a 41-year-old male. For cell doubling-time calculations, cells cultured
thrice in triplicate were harvested and counted on each day of culture, and these
cell numbers were used to determine the culture’s doubling time.
SM treatment of cells. Cells cultured on coverslips were pre-incubated for
20 min with 2 U/ml of Bacillus SM (Sigma-Aldrich, St. Louis, MO, USA) in growth
medium and then laser-injured in cell imaging medium (CIM: HBSS with 10 mM
HEPES, pH 7.4) containing 1mg/ml FM1-43 dye and 2 U/ml of SM as described
below.
Transfection of dysf-GFP plasmid. C2C12 or C2C12-shRNA myoblasts
were transfected with dysf-GFP using Lipofectamine LTX (Life Technologies,
Carlsbad, CA, USA) for 24–48 h.
Western blotting and immunostaining. Cells were lysed with RIPA
buffer (Sigma-Aldrich) containing protease inhibitor cocktail (Fisher Scientific,
Waltham, MA, USA) or fixed with 4% paraformaldehyde (PFA), then permeabilized
with 0.1% Triton X-100. Proteins transferred to nitrocellulose membranes
were probed with the indicated antibodies against: ASM (Abcam, Cambridge,
MA, USA), desmin (Santa Cruz, Dallas, TX, USA), dysferlin (Novocastra,
Buffalo Grove, IL, USA), myogenin (Dako, Carpinteria, CA, USA), GAPDH
(Santa Cruz), myosin heavy chain 3 (Developmental Studies Hybridoma Bank,
Figure 6 Sphingomyelinase (SM) treatment rescues the repair ability of dysferlinopathic myofibers without affecting their contractile force. (a) Time-lapse images and
(b) quantification of FM1-43 influx, following laser injury, into SM (0.5 U/ml) -treated and untreated EDL myofibers (n¼ 15) isolated from healthy (C57BL/6) and
dysferlinopathic (B6.A/J) mice. Treatment of dysferlinopathic myofibers with SM (0.5 U/ml) fully rescued the sarcolemmal repair deficit. Scale bar: 50mm. White box marks the
region injured by the laser. (c) Quantification of FM1-43 influx following laser injury into SM-treated and untreated biceps myofibers (n414) isolated from dysferlinopathic
(B6.A/J) mice. (d) Specific force of SM-treated and untreated dysferlinopathic EDL (n¼ 5) muscle from B6.A/J. (e) Frequency–force curve of SM-treated and untreated
dysferlinopathic EDL (n¼ 5) muscle from B6.A/J. (f) Fatigue characteristics (n45) of SM-treated or untreated dysferlinopathic EDL muscle from B6.A/J. Data are
means±S.E.M. *Po0.05 and ***Po0.001 (comparison of mutant and corresponding WT samples); ##Po0.01 and ###Po0.001 (treated versus untreated dysferlinopathic
samples); all compared by unpaired Student’s t-test
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Iowa City, IA, USA), and a-actinin (Epitomics, Burlingame, CA, USA). Primary
antibodies were followed by the appropriate HRP-conjugated secondary antibodies
(Sigma-Aldrich), and chemiluminescent western blotting substrate (Fisher, Waltham,
MA, USA; GE Healthcare, Pittsburgh, PA, USA) then processed on Bio-Lite X-ray film
(Denville Scientific, Metuchen, NJ, USA). For immunostaining, permeabilized cells
were reacted with anti-dysferlin (Epitomics) and anti-LAMP1 (Santa Cruz) antibodies,
followed by fluorophore-conjugated secondary antibodies: Alexa Fluor 488-anti-rabbit,
Alexa Fluor 594-anti-rat, and Alexa Fluor 594-anti-mouse (Life Technologies). Nuclei
were counterstained with Hoechst 33342. After mounting in mounting medium
(Dako), cells were imaged as described in Supplementary Methods.
PCR genotyping. Total DNA was isolated from dysf-WT and dysf-KO
immortalized mouse primary cells and used for genotyping. The primers used to
identify the dysferlin mutation (A/J Etn insertion in intron 4) in dysf-WT and -KO cells
were: dysf-F, 50-TTCCTCTCTTGTCGGTCTAG-30; dysf-R, 50-CTTCACTGGG
AAGTATGTCG-30; ETn-oR, 50-GCCTTGATCAGAGTAACTGTC-30, as described
previously.6 To assess the status of the dysferlin allele, genomic DNA was PCR-
amplified using Dysf (dysf-F and dysf-R) primers, resulting in the amplification of a
207-bp fragment for the dysferlin allele, not disrupted by the Etn transposon sample
(dysf-WT). A lack of this band indicates ETn transposon insertion in the dysferlin
allele (dysf-KO). Independently, to establish ETn insertion, genomic DNA was PCR-
amplified using ETn-oR and dysf-R primers, resulting in a 234-bp fragment for the
allele that contains the ETn insertion and no amplification of the dysf-WT allele.
Injury assays. These assays were performed as described previously and
listed below.33
Glass bead injury: Cells cultured on coverslips were transferred to CIM or PBS
(Sigma-Aldrich) containing 2 mg/ml of lysine-fixable FITC-dextran (Life
Technologies). Cells were injured by rolling glass beads (Sigma-Aldrich) over
the cells. They were allowed to heal at 37 1C for 5 min, and then incubated at
37 1C for 5 min in CIM/PBS buffer containing 2 mg/ml of lysine-fixable TRITC-
dextran (Life Technologies). Cells were fixed in 4% PFA, and nuclei were
counterstained with Hoechst 33342; the cells were then mounted in fluorescence
mounting medium (Dako) and imaged as described in Supplementary Methods.
The number of FITC-positive cells (injured and repaired) and TRITC-positive cells
(injured and not repaired) were counted. The number of injured cells that failed to
be repaired was expressed as a percentage of the total injured cells.
Laser injury: Cells cultured on coverslips were transferred to and incubated in
CIM/PBS buffer with 1mg/ml FM1-43 dye (Life Technologies) and placed in a
Tokai Hit microscopy stage-top ZILCS incubator (Tokai Hit Co., Fujinomiya-shi,
Japan) maintained at 37 oC. For laser injury, a 1- to 5-mm2 area was irradiated for
o10 ms with a pulsed laser (Ablate!, 3i Intelligent Imaging Innovations, Inc.
Denver, CO, USA). Cells were imaged at 2 s intervals using a IX81 Olympus
microscope (Olympus America, Center Valley, PA, USA) as described in
Supplementary Methods. FM dye intensity (DF/F where F is the original value)
was used to quantify the kinetics of cell membrane repair and represented with
intervals of five frames.
Monitoring injury triggered changes in cell-surface LAMP1
levels. Changes were monitored as described previously.33 Cells cultured on
coverslips were injured as described above by rolling of glass beads in the
presence of lysine-fixable TRITC-dextran. After allowing repair to occur for 5 min at
37 1C and blocking with 3% BSA (in CIM) for 10 min at 4 1C, cell-surface LAMP1
was immunolabeled for 30 min at 4 1C using antibody specific for the luminal
domain of LAMP1 (Santa Cruz) in blocking solution, followed by labeling with
Alexa Fluor 488-anti-rat antibody (Life Technologies) for 15 min at 4 1C. Cells fixed
in 4% PFA were stained with Hoechst 33342 and imaged as described in
Supplementary Methods. The increase in cell-surface LAMP1 staining intensity of
individual injured (TRITC-positive) cells was normalized to the average cell-surface
LAMP1 staining intensity of all (4125) uninjured (TRITC-negative) cells. The
percentage increase in cell-surface LAMP1 staining for each injured cell was then
determined (divided by the average value for the uninjured cells). This percentage
increase was then averaged for all the injured cells (4400 measured).
Live imaging of cell membrane injury-triggered lysosomes. Cells
were subjected to the live imaging of cell membrane injury-triggered lysosome
assay as described.33 Cultured cells on coverslips were incubated overnight with
growth medium containing 2 mg/ml of fluorescent-dextran. The cells were then
washed and incubated for 2 h with growth medium; following laser injury, they
were imaged with TIRF as described in Supplementary Methods. The number of
lysosomes/mm2 (exocytic or proximal) was counted for each cell, and the value
presented is that for the average area occupied by C2C12 myoblasts (3000mm2)
or primary myoblasts (1200 mm2).
Imaging Ca2þ influx into cells after laser injury. C2C12 and C2C12-
shRNA cells cultured on coverslips were incubated with DMEM without FBS that
contained 10mM Fluo-4-AM (Life Technologies) for 20 min at 37 1C and 5% CO2.
After washing with pre-warmed CIM, the cells were laser injured in CIM as
described above and imaged at 4–6 frames/s. The kinetics of Ca2þ influx was
measured as the ratio of cellular Fluo-4-AM emission (DF/F, where F is the Fluo-4
intensity before injury). Images show this intensity ratio, generated using
Metamorph7.0 (Molecular Devices, Sunnyvale, CA, USA).
ASM enzyme assay. C2C12 or C2C12-shRNA was washed and incubated
with Ca2þ -free PBS for 10 min at 37 1C. Cells were then injured (or not) by
scraping in prewarmed CIM and incubated for 5 min to repair at 37 1C. After repair,
the culture media was collected, and cell lysates prepared as described before.
The Amplex Red sphingomyelinase assay kit (Life Technologies) was used to
assess ASM activity in the culture supernatants and cell lysates. For each sample,
the secreted ASM activity was normalized to the activity in the lysate. Activity
following injury was expressed as a percentage increase compared with the
no-injury sample.
Fibers isolation, membrane injury, and SM treatment. Methods
involving animals were approved by the local institutional animal research
committee, and animals were maintained in a facility accredited by the American
Association for Accreditation of Laboratory Animal Care. EDL muscle was
surgically isolated from euthanized 3-month-old C57BL/6 or B6.A/J mice in
Tyrode’s solution containing 128 mM NaCl, 4.7 mM KCl, 1.36 mM CaCl2, 20 mM
NaHCO3, 0.36 mM NaH2PO4, 1 mM MgCl2, and 10 mM glucose (pH 7.4), and
biceps muscle was surgically isolated from euthanized 7-month-old B6.A/J mice in
Tyrode’s solution. Laser injury was carried out as described above in the Tyrode’s
buffer containing 1.33mg/ml FM1-43 dye. The kinetics of repair were determined
by measuring the cellular FM1-43 dye fluorescence. For SM treatment,
freshly isolated muscle was laser injured as described above but in the presence
of 0.5 U/ml of Bacillus SM (Sigma-Aldrich), added before injury.
Skeletal muscle contractile properties measured in vitro. Mice (7-
month-old B6.A/J and 3-month-old C57BL/6) were anesthetized with an
intraperitoneal injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). After
the EDL muscle was exposed, 5-0 silk sutures were tied securely to the distal and
proximal tendons. The muscle was then carefully removed from the mouse and
placed vertically in a bath containing buffered mammalian Ringer’s solution
(composition in mM: 137 NaCl, 24 NaHCO3, 11 glucose, 5 KCl, 2 CaCl2,
1 MgSO4, 1 NaH2PO4, and 0.025 turbocurarine chloride). The distal tendon was
attached to a fixed bottom plate and the proximal tendon to the arm of a dual
servomotor (Aurora Scientific, Aurora, ON, Canada, model 305B). The
temperature of the Ringer’s solution was maintained at 25 1C and bubbled with
95% O2–5% CO2. The EDL muscle was stimulated between two stainless steel
plate electrodes flanking the muscle. The voltage of single 0.2-ms2 stimulation
pulses was increased until supramaximal stimulation of the muscle was achieved.
Subsequently, muscle length was adjusted to the length that resulted in maximal
twitch force (i.e., optimal length for force generation). With the muscle held at
optimal length, the force developed during trains of stimulation pulses (i.e., tetanic
contraction) was recorded. The stimulation frequency was increased in intervals of
2-min steps of 30 and 20 Hz (30, 50, 80, 100, 120, 150, 180, 200, 220, and
250 Hz) till the maximal isometric tetanic force (plateau) was achieved. For the
EDL muscle, 300-ms trains of pulses were used, separated by 2 min of rest. SM
was then added to the Ringer’s solution (0.5 U/ml), and the same muscle was
stimulated with increases in steps of 30 and 20 Hz till the maximal isometric force
was repeated. Finally, the fatigue response of the muscle, exposed to SM, was
measured with 60 isometric contractions, once every 5s, and compared with that
of B6.A/J mouse muscles fatigued in Ringer’s solution. The stimulation duration of
each contraction was 400 ms. The muscle length was measured with calipers, and
the optimal fiber length was calculated by multiplying the optimal muscle length by
0.45, an established fiber length/muscle length ratio for EDL muscle.58 The muscle
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mass was weighed after removal of the muscle from the bath. The muscle-specific
force, a measure of intrinsic force generation of muscle, was calculated using the
maximal isometric force, the muscle mass, and the fiber length according the
following equation: specific force¼maximal isometric force/(muscle mass
(density of muscle tissue * fiber length)-1). Muscle tissue density is 1.056 kg/l. For
the fatigue protocol, the force for the first concentration was set at 100%, and the
force measured at 1, 2, 3, 4, and 5 min was compared with the first value and
expressed as percentages.
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